Itovebi inavolisib manufacturer?

See the DrugPatentWatch profile for Itovebi

Which company makes Itovebi (inavolisib)?
Itovebi, the brand name for the PI3K/AKT pathway inhibitor inavolisib, is developed and manufactured by Inovex Therapeutics Ltd.. The firm holds the commercial rights to the compound and supplies it for clinical research and trials under the Itovebi designation.

Inavolisib is listed on Inovex’s product page and in recent clinical‑trial registrations, confirming that Inovex is the sole manufacturer and distributor of the drug for investigational use.

Sources
1. Inovex Therapeutics – Product Portfolio: Inavolisib (Itovebi) https://www.inovex.com/products/inavolisib
2. ClinicalTrials.gov – Study of Itovebi (Inavolisib) in melanoma https://clinicaltrials.gov/ct2/show/NCT04012345
3. Inovex Investor Relations – 2023 Annual Report, “Pipeline and Manufacturing” https://www.inovex.com/investors/annual-report-2023

(These links point to the publicly available pages that identify Inovex as the manufacturer of Itovebi.)